Status:
UNKNOWN
Registry on NEN Patients and COVID-19
Lead Sponsor:
European Institute of Oncology
Conditions:
Neuroendocrine Tumors
COVID-19
Eligibility:
All Genders
18+ years
Brief Summary
A huge number of initiatives about COVID-19 are ongoing and a growing number of publications regard the correlation between cancer patients in general and SARS-CoV-2 infection. Although it has been re...
Detailed Description
At the end of December 2019, several cases of pneumonia of unknown origin were diagnosed in Wuhan, in the province of Hubei, China. These cases have been linked to a new beta-coronavirus (COVID-19), i...
Eligibility Criteria
Inclusion
- Patients \> 18 y.o.
- Patients with a NEN of any type with a positive SARS-CoV-2 swab (RT-PCR).
- Patients with SARS-CoV-2 positivity (RT-PCR) who are asymptomatic or with symptoms/signs of COVID-19.
- Patients with a NEN on active treatment.
- Patients with macroscopic evidence of NEN or with no evidence of NEN (if they received surgical +/- locoregional non-surgical treatments within the last 2 months)
- Able to provide signed written informed consent
Exclusion
- Patients with NEN and symptoms suspected for COVID-19 who did not undergo SARS-CoV-2 swab (RT-PCR).
- Patients with small cell lung cancer.
- Patients with non-pure NEN (e.g. MiNEN).
Key Trial Info
Start Date :
June 15 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 15 2023
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04444401
Start Date
June 15 2020
End Date
December 15 2023
Last Update
June 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
European Institute of Oncology, IEO, IRCCS
Milan, MI, Italy, 20141